scholarly journals MP05-04 CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION RATES ON MRI GUIDED FUSION NEEDLE BIOPSY - EXPERIENCE FROM THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATIVE

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Ako Adams Ako ◽  
Serge Ginzburg ◽  
Eric Singer ◽  
Bruce Jacobs ◽  
Claudette Fonshell ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2502
Author(s):  
August Sigle ◽  
Cordula A. Jilg ◽  
Timur H. Kuru ◽  
Nadine Binder ◽  
Jakob Michaelis ◽  
...  

Background: Systematic biopsy (SB) according to the Ginsburg scheme (GBS) is widely used to complement MRI-targeted biopsy (MR-TB) for optimizing the diagnosis of clinically significant prostate cancer (sPCa). Knowledge of the GBS’s blind sectors where sPCa is missed is crucial to improve biopsy strategies. Methods: We analyzed cancer detection rates in 1084 patients that underwent MR-TB and SB. Cancerous lesions that were missed or underestimated by GBS were re-localized onto a prostate map encompassing Ginsburg sectors and blind-sectors (anterior, central, basodorsal and basoventral). Logistic regression analysis (LRA) and prostatic configuration analysis were applied to identify predictors for missing sPCa with the GBS. Results: GBS missed sPCa in 39 patients (39/1084, 3.6%). In 27 cases (27/39, 69.2%), sPCa was missed within a blind sector, with 17/39 lesions localized in the anterior region (43.6%). Neither LRA nor prostatic configuration analysis identified predictors for missing sPCa with the GBS. Conclusions: This is the first study to analyze the distribution of sPCa missed by the GBS. GBS misses sPCa in few men only, with the majority localized in the anterior region. Adding blind sectors to GBS defined a new sector map of the prostate suited for reporting histopathological biopsy results.


2003 ◽  
Vol 169 (1) ◽  
pp. 130-135 ◽  
Author(s):  
JEAN O. UNG ◽  
IGNACIO F. SAN FRANCISCO ◽  
MEREDITH M. REGAN ◽  
WILLIAM C. DeWOLF ◽  
ARIA F. OLUMI

Urology ◽  
2005 ◽  
Vol 66 (1) ◽  
pp. 130-134 ◽  
Author(s):  
Takashi Kobayashi ◽  
Kenji Mitsumori ◽  
Koji Nishizawa ◽  
Takashi Kawahara ◽  
Keiji Ogura ◽  
...  

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Christopher B. Riedinger ◽  
Susan Linsell ◽  
Jun Ye ◽  
Rodney Dunn ◽  
James E. Montie ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Maudy C. W. Gayet ◽  
Anouk A. M. A. van der Aa ◽  
Harrie P. Beerlage ◽  
Bart Ph Schrier ◽  
Maaike Gielens ◽  
...  

Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands. Results. Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB. Conclusions. There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.


2020 ◽  
Vol 53 (1) ◽  
pp. 283-291
Author(s):  
Tsutomu Tamada ◽  
Ayumu Kido ◽  
Akira Yamamoto ◽  
Mitsuru Takeuchi ◽  
Yoshiyuki Miyaji ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document